Shimadzu to Collaborate with Phenomenome in Biomarker Discovery, Proteomic Studies
Shimadzu and Phenomenome Discoveries have agreed to collaborate exclusively to develop tools for biomarker discovery and global profiling studies, including proteomic studies, the companies said this week.
A year ago, Shimadzu and Phenomenome inked a deal that allowed researchers to use Phenomenome's informatics platform to visualize and interpret mass spectrometry data generated by Shimadzu technology for metabolomics research.
The current agreement extends this previous agreement by further integrating mass spectrometry data generated on Shimadzu's LCMS-IT-TOF systems with Phenomenome's Profiler informatics platform, Shimadzu said.
"The collaboration with Phenomenome has been enhanced to take into account the growing need of researchers working in biomarker discovery and comparative proteomics studies to use high mass accuracy MSn data," said Kozo Shimazu, Shimadzu's deputy general manager in the analytical and measuring instrument division. "We believe that this collaboration ... helps deliver a unique and integrated solution to help find components of biological significance."
Capital Bio To Distribute BioMachines Automation Tools in Asia
Biomachines announced this week that it has signed an exclusive distribution agreement with Beijing-based Capital Bio.
The agreement will allow BioMachines to expand its sales channel beyond North America and Europe into China, Taiwan, and Hong Kong.
BioMachines sells automation tools for drug discovery and proteomic research, including automated front-end sample preparation for MALDI mass spectrometry analysis, pathogen detection device development, and proteomic services.
AlgoNomics and Mat Biopharma to Collaborate on Cancer Drug Development
AlgoNomics will use its structural bioinformatics platform to analyze antibody leads in Mat Biopharma's therapeutic development program in hematological cancer and other solid cancers, the companies said last week.
Financial terms of the agreement were not disclosed.
Strategic Diagnostics Pens Genomic Antibodies Deal With Undisclosed Big Pharma
An undisclosed "top ten" pharmaceutical company has placed an "initial order" with Strategic Diagnostics for its Genomic Antibodies technology, Strategic Diagnostics said this week.
The company said that scientists for this drug maker "have unsuccessfully attempted to make antibodies to some of the protein targets in this initial order," which they hope to reverse with Genomic Antibodies.
Strategic Diagnostics said this represents the third "major" pharmaceutical customer to initiate a relationship with the company, "and although these represent initially small projects, we are increasingly confident in the commercial viability of this capability."
Strategic Diagnostics' most-recent deal before this one was with Berlex in April.
Syngene Says Undisclosed Pharma Is Using Its Imaging Tech to Find Protein Targets
Syngene last week said that an undisclosed "leading US pharmaceutical company" is using its imaging system to help it discover protein drug targets.
Researchers at this drug maker are using the technology to automatically assess around 150 2D protein gels per week. These gels are up to 26 cm x 26 cm and are stained with dyes including Sypro Orange, Sypro Ruby, Sybr Green, Coomassie Blue, and Pro-Q Diamond.
Financial terms of the deal were not disclosed.